Friedl-Naderer Johanna 4
4 · Dyne Therapeutics, Inc. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Dyne Therapeutics CCO Johanna Friedl-Naderer Sells 148 Shares
What Happened
Johanna Friedl‑Naderer, Chief Commercial Officer of Dyne Therapeutics (DYN), reported the sale of 148 shares on 2026-03-05 at $14.90 per share, totaling $2,205. The shares were automatically sold to cover tax withholding related to the vesting of restricted stock units (RSUs) and do not represent a discretionary trade.
Key Details
- Transaction date: 2026-03-05; Sale price: $14.90 per share; Shares sold: 148; Proceeds: $2,205.
- Footnote: The sale was automatic under an RSU agreement to satisfy tax withholding obligations and is described as a "binding contract" consistent with a Rule 10b5‑1 affirmative defense (i.e., not a discretionary sale).
- Holdings noted in the filing include 129,790 unvested RSUs.
- Filing date: 2026-03-06 for a 2026-03-05 transaction — filed promptly (not marked late).
Context
Tax‑withholding sales following RSU vesting are common and typically administrative; they do not necessarily signal insider sentiment about the company's prospects. For retail investors, outright purchases are generally more informative about insider confidence than routine withholding sales.
Insider Transaction Report
Form 4
Friedl-Naderer Johanna
Chief Commercial Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-03-05$14.90/sh−148$2,205→ 154,581 total
Footnotes (2)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- [F2]Includes 129,790 unvested RSUs.
Signature
/s/ Ron Caponigro, Attorney-in-Fact|2026-03-06